Chronic wounds include, but are not limited to diabetic foot ulcers (DFU), venous leg ulcers (VLU), and pressure ulcers (PU) that do not progress through the healing process in a timely manner. This case series aims to investigate the recovery of chronic wounds treated with Cellmax®, which contains secretory factors, bioactives and bioproteins from mesenchymal stem cell (MSC) secretome, based on a standard debridement procedure for wound healing and application of subcutaneous injection of Cellmax as first-line therapy. Seven patients with different underlying comorbidities consented to participate in the case study for varying treatment duration at the Wound Care Unit, Department of Internal Medicine, Hospital Kuala Lumpur, Malaysia. The inclusion criteria include patients with chronic wounds classified as Class 2 and Class 3 as according to Harikrishna Periwound skin classification (HSPC). One patient out of seven patients, saw no reduction in wound size, whereas all other had reduced the wound size and the formation of granulation tissues were observed in all patients over time from week 1 to week 6 after therapy. Cellmax® was also found to be highly tolerable and good safety profile among these seven chronic wound patients.